Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M LoRusso

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Investigational New Drugs|June 11, 2003
A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" designS M Gadgeel, R R Boinpally, L K Heilbrun, et al.
Investigational New Drugs|January 1, 1996
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeksB J Foster, P M LoRusso, E Poplin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ L Blum, S E Jones, A U Buzdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Investigational New Drugs|June 11, 2003
A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" designS M Gadgeel, R R Boinpally, L K Heilbrun, et al.
Investigational New Drugs|January 1, 1996
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeksB J Foster, P M LoRusso, E Poplin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ L Blum, S E Jones, A U Buzdar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Pageof 3